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I-1 OARSI AND NICE: ARE THEY BETTER THAN PREVIOUS
GUIDELINES?
G. Nuki1, R. Moskowitz2, W. Zhang3. 1University of Edinburgh,
Edinburgh, UNITED KINGDOM, 2Case Western Reserve University,
Cleveland, OH, USA, 3University of Nottingham, Nottingham, UNITED
KINGDOM
Purpose: In recent years guidelines for the treatment of osteoarthritis
(OA) have been criticised for lack of methodological rigour, stakeholder
involvement and applicability. The Osteoarthritis Research Society Inter-
national (OARSI) has recently published global evidence-based, expert-
consensus treatment guidelines for OA hip and knee [1,2]. The National
Institute for Health and Clinical Excellence (NICE) has also recently
published a National Clinical Guideline for the Care and Management
of OA in the National Health Service (NHS) in Great Britain [3]. The aim
of this study was to attempt to assess whether the OARSI and NICE
recommendations were any better than previous guidelines.
Methods: The quality of the guidelines was assessed using the AGREE
(Appraisal of Guidelines for Research and Evaluation) instrument and
standardised percent scores for scope, stakeholder involvement, rigour,
clarity, applicability and editorial independence, as well as overall qual-
ity were calculated. Assessments were undertaken by an international
panel of 7 independent experts from a variety of health professional
disciplines. Scores were also compared with AGREE appraisals of the
OARSI guidelines undertaken by 4 scientists from the American Academy
of Orthopaedic Surgeons (AAOS) and with the appraisals of the 23
previously published guidelines [2].
Results: Both OARSI and NICE guidelines had higher scores for each
domain of quality than previously published guidelines. The OARSI rec-
ommendations scored higher than the NICE guidelines for methodological
rigour (70% v 59%), editorial independence (75% v 48%) and overall
quality (58% v 50%), but had lower scores for stakeholder involvement
(42% v 49%), clarity (59% v 64%) and especially applicability (22% v
43%).
Conclusions: Appraisals of the OARSI and NICE guidelines suggest
that they are better in overall quality and in most quality domains than
previous guidelines. Nevertheless the quality of both could be signiﬁcantly
improved by wider stakeholder involvement and greater attention to
applicability. This is clearly a greater challenge for globally applicable
international guidelines than it is for a national guideline. The OARSI
guidelines can be adapted for national and regional application through
translation and liason with patients and professional groups representing
stakeholders in primary and secondary care worldwide [1].
References
[1] 1. Zhang W et al Osteoarthritis and Cartilage 2008; 16: 137−62.
[2] 2. Zhang W et al Osteoarthritis and Cartilage 2007: 15: 981–1000.
[3] 3. National Collaborating Centre for Chronic Conditions. adults. Os-
teoarthritis: National clinical guidelines for care and management in
http://www.nice.org.uk/nicemedia/pdf/CG059FullGuideline.pdf
I-2 NEW EVIDENCE 2006–2008: WHAT IMPACT ON CURRENT
RECOMMENDATIONS?
W. Zhang1, R.W. Moskowitz2. 1Nottingham University, Nottingham,
UNITED KINGDOM, 2Case Western Reserve University, Beachwood,
OH, USA
Purpose: The Osteoarthritis Research Society International (OARSI)
developed global, evidence-based consensus treatment guidelines for
osteoarthritis (OA) of the hip and knee based on a systematic review
(SR) of the literature up to January 2006 [1,2]. Since then a large number
of new studies have been published. This study was designed to update
the evidence and to examine whether the more recent evidence would
inﬂuence the proﬁle of recommendations for core therapies for OA.
Methods: A systematic literature search was undertaken for new guide-
lines, SRs, randomised controlled trials (RCTs) and economic evaluations
(EEs) published between 31 January 2006 and 31 January 2008. The
quality of guidelines was appraised by an independent group of experts
and the core set of treatment modalities was determined by the level of
evidence and the frequency of recommendations. The quality of the RCTs
included in the SRs and of others retrieved from the literature search
were appraised, and where possible effect size (ES), number needed to
treat (NNT), relative risks (RR) or odds ratio (OR) and cost per quality
adjusted life years (QALY) gained were estimated. Statistical pooling was
undertaken as appropriate. Sensitivity analysis and cumulative meta-
analysis were conducted to examine the impact of studies published after
2006 and the stability of the effect.
Results: The literature search yielded 1347 citations in the last 2 years.
Of these 2 guidelines, 57 SRs, 200 RCTs and 16 EEs met inclusion
criteria. Core therapies, deﬁned as treatments supported by Ia level
evidence and a recommendation by all guidelines which addressed
that therapy, remained unchanged. These included exercise, education,
self-management, acetaminophen and COX-2 selective or non-selective
NSAIDs with PPI. Whilst the evidence for weight reduction was upgraded
from Ib to Ia, the frequency of recommendations for joint lavage was
reduced from 100% to 75%. ES changed with inclusion of additional trials.
For example the ES for pain relief was reduced from 0.21 (95%CI 0.02,
0.41) to 0.18 (0.04, 0.33) for acetaminophen, but was increased from 0.13
(−0.12, 0.38) to 0.20 (0.06, 0.33) for weight reduction. Cumulative meta-
analysis indicated stability of efﬁcacy for some therapies (eg, NSAIDs) but
not for others (eg, glucosamine and chondroitin sulphate). New treatment
modalities such as celecoxib plus PPI and Tai Chi exercise had been
assessed in RCTs. Cost per QALY had been estimated for behavioural
graded activity, class based exercise, unicompartment knee arthropathy,
and hip versus knee replacements.
Conclusions: Recent research evidence has resulted in changes in
the calculated risk-beneﬁt ratio for some treatments for osteoarthritis.
The rapid increase of new evidence presents challenges to guideline
developers. A regularly updated, evidence-based osteoarthritis research
database of well characterised trials of all modalities of treatment for OA
would be very useful.
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I-3 IS BEST AVAILABLE EVIDENCE THE BEST?
J.M. Bjordal1,2. 1Bergen University College, Bergen, NORWAY,
2University of Bergen, Bergen, NORWAY
Purpose: Evaluation of some of the pitfalls associated with comparisons
of the numerous interventions used in osteoarthritis management.
Methods: Literature review of systematic reviews and overviews with sen-
sitivity analysis of patient selection bias, interpretation of effect estimates,
level of evidence and strength of recommendation in osteoarthritis.
Results: Guidelines are often seen as the end results of a stringent
synthesis of the available literature. However, the picture of an unblem-
ished and rigorous scientiﬁc method for synthesizing scientiﬁc evidence
has been taking several blows lately. The method quality scoring of
randomized controlled trials (RCT) has proved less reliable than we hoped
for, and the interpretation of meta-analyses with mixed results seems
unreliable even among experienced reviewers. Methods for grading levels
of evidence are drifting from quantiﬁcation of a number of well-designed
RCTs or a single meta-analysis number to achieve the highest evidence
level, to qualitative evaluation of the likelihood for future change in
evidence. And recommendations are subject to a qualitative balancing
act of beneﬁt and harms. Guidelines can be seen as an anchor point
on a continuous line from (a) perfect consensus of experts on one side
